INCY
Incyte Corporation
NASDAQ · USHealthcareBiotechnology
$115.65-1.36%
Price as of Jul 20, 2026
INCY financials
Incyte Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $5.1B | $4.2B | $3.7B | $3.4B |
| Cost of revenue | $372.1M | $312.1M | $255.0M | $207.0M |
| Gross profit | $4.8B | $3.9B | $3.4B | $3.2B |
| Operating expenses | $3.4B | $3.8B | $2.8B | $2.6B |
| Operating income | $1.3B | $101.3M | $655.4M | $591.6M |
| Net income | $1.3B | $32.6M | $597.6M | $340.7M |
| EBITDA | $1.8B | $408.2M | $919.4M | $599.6M |
| Basic EPS | $6.59 | $0.16 | $2.67 | $1.53 |
| Diluted EPS | $6.41 | $0.15 | $2.65 | $1.52 |
| Balance sheet | ||||
| Cash & equivalents | $3.1B | $1.7B | $3.2B | $3.0B |
| Total assets | $7.0B | $5.4B | $6.8B | $5.8B |
| Total liabilities | $1.8B | $2.0B | $1.6B | $1.5B |
| Stockholders’ equity | $5.2B | $3.4B | $5.2B | $4.4B |
| Total debt | $69.4M | $43.5M | $38.3M | $41.5M |
| Net debt | -$3.0B | -$1.6B | -$3.2B | -$2.9B |
| Cash flow | ||||
| Operating cash flow | $1.4B | $335.3M | $496.5M | $969.9M |
| Capital expenditure | -$58.9M | -$86.3M | -$47.5M | -$77.8M |
| Free cash flow | $1.4B | $249.1M | $449.0M | $892.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$19.1M | -$2.0B | $0.00 | $0.00 |